Sysmex set to trump German rival in NICE breast cancer metastases test assessment
This article was originally published in Clinica
Sysmex UK is on course to gain exclusive approval for routine UK NHS use of its RD100i OSNA system for sentinel node testing during breast cancer surgery.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.